These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 34646276)
1. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. Shrestha LB; Tedla N; Bull RA Front Immunol; 2021; 12():752003. PubMed ID: 34646276 [TBL] [Abstract][Full Text] [Related]
2. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
3. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
4. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Vanshylla K; Fan C; Wunsch M; Poopalasingam N; Meijers M; Kreer C; Kleipass F; Ruchnewitz D; Ercanoglu MS; Gruell H; Münn F; Pohl K; Janicki H; Nolden T; Bartl S; Stein SC; Augustin M; Dewald F; Gieselmann L; Schommers P; Schulz TF; Sander LE; Koch M; Łuksza M; Lässig M; Bjorkman PJ; Klein F Cell Host Microbe; 2022 Jan; 30(1):69-82.e10. PubMed ID: 34973165 [TBL] [Abstract][Full Text] [Related]
5. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening. Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229 [TBL] [Abstract][Full Text] [Related]
6. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants. Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH MAbs; 2022; 14(1):2021601. PubMed ID: 35030983 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126 [TBL] [Abstract][Full Text] [Related]
8. Broad sarbecovirus neutralization by a human monoclonal antibody. Tortorici MA; Czudnochowski N; Starr TN; Marzi R; Walls AC; Zatta F; Bowen JE; Jaconi S; Di Iulio J; Wang Z; De Marco A; Zepeda SK; Pinto D; Liu Z; Beltramello M; Bartha I; Housley MP; Lempp FA; Rosen LE; Dellota E; Kaiser H; Montiel-Ruiz M; Zhou J; Addetia A; Guarino B; Culap K; Sprugasci N; Saliba C; Vetti E; Giacchetto-Sasselli I; Fregni CS; Abdelnabi R; Foo SC; Havenar-Daughton C; Schmid MA; Benigni F; Cameroni E; Neyts J; Telenti A; Virgin HW; Whelan SPJ; Snell G; Bloom JD; Corti D; Veesler D; Pizzuto MS Nature; 2021 Sep; 597(7874):103-108. PubMed ID: 34280951 [TBL] [Abstract][Full Text] [Related]
9. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. de Mattos Barbosa MG; Liu H; Huynh D; Shelley G; Keller ET; Emmer BT; Sherman E; Ginsburg D; Kennedy AA; Tai AW; Wobus C; Mirabeli C; Lanigan TM; Samaniego M; Meng W; Rosenfeld AM; Prak ETL; Platt JL; Cascalho M JCI Insight; 2021 May; 6(9):. PubMed ID: 33769311 [TBL] [Abstract][Full Text] [Related]
10. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459 [TBL] [Abstract][Full Text] [Related]
11. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance. Zou J; Li L; Zheng P; Liang W; Hu S; Zhou S; Wang Y; Zhao J; Yuan D; Liu L; Wu D; Xu M; Zhang F; Zhu M; Wu Z; Cao X; Ni M; Ling X; Wu Y; Kuang Z; Hu M; Li J; Li X; Guo X; Xu T; Jiang H; Gao C; Yu M; Liu J; Zhong N; Zhou J; Huang JA; Jin T; He J J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35108220 [TBL] [Abstract][Full Text] [Related]
12. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823 [TBL] [Abstract][Full Text] [Related]
13. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691 [TBL] [Abstract][Full Text] [Related]
14. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies. Li S; Wu J; Jiang W; He H; Zhou Y; Wu W; Gao Y; Xie M; Xia A; He J; Zhang Q; Han Y; Wang N; Zhu G; Wang Q; Zhang Z; Mayer CT; Wang K; Wang X; Wang J; Chen Z; Jiang S; Sun L; Xia R; Wang Q J Med Virol; 2023 Feb; 95(2):e28440. PubMed ID: 36573441 [TBL] [Abstract][Full Text] [Related]
15. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Li T; Xue W; Zheng Q; Song S; Yang C; Xiong H; Zhang S; Hong M; Zhang Y; Yu H; Zhang Y; Sun H; Huang Y; Deng T; Chi X; Li J; Wang S; Zhou L; Chen T; Wang Y; Cheng T; Zhang T; Yuan Q; Zhao Q; Zhang J; McLellan JS; Zhou ZH; Zhang Z; Li S; Gu Y; Xia N Nat Commun; 2021 Sep; 12(1):5652. PubMed ID: 34580306 [TBL] [Abstract][Full Text] [Related]
16. Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. Wilhelm A; Toptan T; Pallas C; Wolf T; Goetsch U; Gottschalk R; Vehreschild MJGT; Ciesek S; Widera M Viruses; 2021 Aug; 13(9):. PubMed ID: 34578275 [TBL] [Abstract][Full Text] [Related]
17. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
19. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510 [TBL] [Abstract][Full Text] [Related]